This was especially important to consider given the expansion of the use of GLP-1 medications in treating multiple health issues beyond type 2 diabetes and obesity—especially for women’s health, which had historically been understudied and underfunded [57]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.